Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hoechst Teczem enalapril/diltiazem combo will be launched in 1997 as second-line antihypertensive.

Executive Summary

HOECHST TECZEM (ENALAPRIL/DILTIAZEM) APPROVED FOR SECOND-LINE HYPERTENSION use by FDA Oct. 4. Hoechst Marion Roussel's Teczem is indicated for patients whose hypertension is not controlled satisfactorily by the angiotensin-converting enzyme inhibitor enalapril (Merck's Vasotec) or the calcium channel blocker diltiazem (Hoechst's Cardizem CD) individually or if "the dose of one or the other monotherapy cannot be increased further because of dose-limiting side effects," labeling states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel